Kite and Pregene Begin In Vivo BCMA CAR T Dosing in China
On its 29 October earnings call Gilead said patients have begun dosing in a China investigator-initiated trial of an in vivo BCMA CAR-T program with Shenzhen Pregene. The newly disclosed dosing is a clinical…
